|
시장보고서
상품코드
2049616
텔미사르탄(Telmisartan) 시장 보고서 : 적응증별, 유통 채널별, 지역별(2026-2034년)Telmisartan Market Report by Indication (Hypertension, Cardiovascular Risk Reduction), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Stores), and Region 2026-2034 |
||||||
세계의 텔미사르탄 시장 규모는 2025년에 39억 달러에 달했습니다. 향후 IMARC Group은 2034년까지 시장 규모가 49억 달러에 달하고, 2026년부터 2034년까지 CAGR 2.49%로 성장할 것으로 예측했습니다.
텔미사르탄은 비펩타이드성 안지오텐신 수용체 길항제(ARB)로 고혈압 및 심혈관질환 치료제로 처방되고 있습니다. 일반적으로 정제 또는 경구용 유성 현탁액 형태로 제공되며, 효과를 높이기 위해 다른 약물과 병용하여 사용됩니다. 본 제제는 항고혈압 작용을 나타내며, 체내 알도스테론 생성을 억제하여 나트륨 및 수분 흡수를 감소시켜 혈압을 낮추는 효과가 있습니다. 텔미사르탄은 또한 혈관을 이완시키고 신장 기능을 촉진합니다. 하지만 어지럼증, 현기증, 기침, 부비동통 등 다양한 부작용을 유발할 수 있습니다.
텔미사르탄 시장 동향:
세계 제약 산업의 괄목할만한 성장은 시장의 밝은 전망을 만드는 주요 요인 중 하나입니다. 또한, 고혈압, 당뇨병 및 다양한 신장 관련 질환의 유병률 증가는 시장 성장을 촉진하고 있습니다. 텔미사르탄은 인슐린 감수성을 높이기 위한 유전자 변형과 당-지질 대사 조절에 효과적임이 입증되어 만성 당뇨병성 신장질환 및 좌식 생활습관으로 인한 기타 질환 관리에 도움을 줄 수 있습니다. 제약사들은 또한 고혈압 및 심혈관질환에 대한 비용 효율적인 치료를 제공하기 위해 텔미사르탄 제제의 제네릭 의약품을 출시하고 있습니다. 또한, 제약사들은 당뇨병성 신증 치료를 위한 첨단 텔미사르탄 제제 연구개발(R&D)에 많은 투자를 하고 있으며, 이 또한 시장 성장에 기여하고 있습니다. 고령 인구의 증가와 의료 인프라의 획기적인 개선 등 다른 요인들도 시장의 추가 확장을 견인할 것으로 예상됩니다.
본 보고서에서 답변하는 주요 질문
- 지금까지 세계 텔미사르탄 시장은 어떻게 성장해 왔으며, 향후 몇 년 동안은 어떻게 변화할 것인가?
- COVID-19는 세계 텔미사르탄 시장에 어떤 영향을 미쳤는가?
- 주요 지역 시장은 어디인가?
- 적응증별 시장 현황은 어떠한가?
- 유통 채널별 시장 현황은 어떠한가?
- 이 산업의 가치사슬에서 각 단계는 어떤 역할을 하는가?
- 이 산업의 주요 촉진요인과 과제는 무엇인가?
- 세계 텔미사르탄 시장의 구조는 무엇이며, 주요 플레이어는 누구인가?
- 업계 내 경쟁은 어느 정도 치열한가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 텔미사르탄 시장
제6장 시장 내역 : 적응증별
제7장 시장 내역 : 유통 채널별
제8장 시장 내역 : 지역별
제9장 SWOT 분석
제10장 밸류체인 분석
제11장 Porter's Five Forces 분석
제12장 가격 분석
제13장 경쟁 구도
KSM 26.06.10The global telmisartan market size reached USD 3.9 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 4.9 Billion by 2034, exhibiting a growth rate (CAGR) of 2.49% during 2026-2034.
Telmisartan is a non-peptide angiotensin receptor blocker (ARB), which is used as a prescription drug for the treatment of hypertension and cardiovascular disorders. It is commonly available in tablets and oral oil suspension variants and is administered with other medications to enhance its efficacy. It exhibits antihypertensive properties and inhibits aldosterone production in the body, thereby leading to a decrease in sodium and water absorption and subsequent reduction in the blood pressure. Telmisartan also relaxes the blood vessels and promotes kidney function. However, it may cause various side effects, such as dizziness, lightheadedness, cough and sinus pain.
TELMISARTAN MARKET TRENDS:
Significant growth in the pharmaceutical industry across the globe is one of the key factors creating a positive outlook for the market. Moreover, the increasing prevalence of high blood pressure, diabetes and various kidney-related disorders is providing a thrust to the market growth. Telmisartan has been proven effective in modifying genes for insulin sensitization and regulating glucose and lipid metabolism, which aids in managing chronic diabetic kidney disease and other disorders caused by sedentary lifestyles. Pharmaceutical manufacturers are also launching generic versions of telmisartan medications to provide cost-effective treatment to hypertension and cardiovascular ailments. Additionally, drug manufacturers are investing significantly in the research and development (R&D) of advanced telmisartan medications for the treatment of diabetic nephropathy, which is also contributing to the growth of the market. Other factors, including the rising geriatric population, along with significant improvements in the healthcare infrastructure, are anticipated to drive the market further.
KEY MARKET SEGMENTATION:
Breakup by Indication:
- Hypertension
- Cardiovascular Risk Reduction
Breakup by Distribution Channel:
- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Stores
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Aurobindo Pharma USA, Boehringer Ingelheim International GmbH, Cipla Limited, Hikma Pharmaceuticals plc, Jubilant Cadista Pharmaceutical, Sanofi S.A., Solco Healthcare (Prinston Pharmaceutical Inc.) and Torrent Pharmaceuticals Ltd.
KEY QUESTIONS ANSWERED IN THIS REPORT
- How has the global telmisartan market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global telmisartan market?
- What are the key regional markets?
- What is the breakup of the market based on the indication?
- What is the breakup of the market based on the distribution channel?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global telmisartan market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Telmisartan Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Indication
- 6.1 Hypertension
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Cardiovascular Risk Reduction
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
7 Market Breakup by Distribution Channel
- 7.1 Hospital Pharmacies
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Drug Stores and Retail Pharmacies
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Online Stores
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
8 Market Breakup by Region
- 8.1 North America
- 8.1.1 United States
- 8.1.1.1 Market Trends
- 8.1.1.2 Market Forecast
- 8.1.2 Canada
- 8.1.2.1 Market Trends
- 8.1.2.2 Market Forecast
- 8.1.1 United States
- 8.2 Asia-Pacific
- 8.2.1 China
- 8.2.1.1 Market Trends
- 8.2.1.2 Market Forecast
- 8.2.2 Japan
- 8.2.2.1 Market Trends
- 8.2.2.2 Market Forecast
- 8.2.3 India
- 8.2.3.1 Market Trends
- 8.2.3.2 Market Forecast
- 8.2.4 South Korea
- 8.2.4.1 Market Trends
- 8.2.4.2 Market Forecast
- 8.2.5 Australia
- 8.2.5.1 Market Trends
- 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
- 8.2.6.1 Market Trends
- 8.2.6.2 Market Forecast
- 8.2.7 Others
- 8.2.7.1 Market Trends
- 8.2.7.2 Market Forecast
- 8.2.1 China
- 8.3 Europe
- 8.3.1 Germany
- 8.3.1.1 Market Trends
- 8.3.1.2 Market Forecast
- 8.3.2 France
- 8.3.2.1 Market Trends
- 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
- 8.3.3.1 Market Trends
- 8.3.3.2 Market Forecast
- 8.3.4 Italy
- 8.3.4.1 Market Trends
- 8.3.4.2 Market Forecast
- 8.3.5 Spain
- 8.3.5.1 Market Trends
- 8.3.5.2 Market Forecast
- 8.3.6 Russia
- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
- 8.3.7.1 Market Trends
- 8.3.7.2 Market Forecast
- 8.3.1 Germany
- 8.4 Latin America
- 8.4.1 Brazil
- 8.4.1.1 Market Trends
- 8.4.1.2 Market Forecast
- 8.4.2 Mexico
- 8.4.2.1 Market Trends
- 8.4.2.2 Market Forecast
- 8.4.3 Others
- 8.4.3.1 Market Trends
- 8.4.3.2 Market Forecast
- 8.4.1 Brazil
- 8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast
9 SWOT Analysis
- 9.1 Overview
- 9.2 Strengths
- 9.3 Weaknesses
- 9.4 Opportunities
- 9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Abbott Laboratories
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.1.4 SWOT Analysis
- 13.3.2 Aurobindo Pharma USA
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.2.3 Financials
- 13.3.3 Boehringer Ingelheim International GmbH
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.4 Cipla Limited
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.4.3 Financials
- 13.3.4.4 SWOT Analysis
- 13.3.5 Hikma Pharmaceuticals plc
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.5.3 Financials
- 13.3.5.4 SWOT Analysis
- 13.3.6 Jubilant Cadista Pharmaceutical
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.7 Sanofi S.A.
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.7.3 Financials
- 13.3.7.4 SWOT Analysis
- 13.3.8 Solco Healthcare (Prinston Pharmaceutical Inc.)
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.9 Torrent Pharmaceuticals Ltd
- 13.3.9.1 Company Overview
- 13.3.9.2 Product Portfolio
- 13.3.9.3 Financials
- 13.3.9.4 SWOT Analysis
- 13.3.1 Abbott Laboratories
